| Recovery Counseling, Llc | |
|
646 Route 18 Building A, Suite 100a East Brunswick NJ 08816-3722 | |
| (732) 236-0494 | |
| Not Available |
| Full Name | Recovery Counseling, Llc |
|---|---|
| Speciality | Counselor |
| Location | 646 Route 18, East Brunswick, New Jersey |
| Authorized Official Name and Position | Michael Solinski (CEO) |
| Authorized Official Contact | 7324396036 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Recovery Counseling, Llc 1376 Peoria Pl North Brunswick NJ 08902-1605 Ph: () - | Recovery Counseling, Llc 646 Route 18 Building A, Suite 100a East Brunswick NJ 08816-3722 Ph: (732) 236-0494 |
| NPI Number | 1154789352 |
|---|---|
| Provider Enumeration Date | 02/02/2016 |
| Last Update Date | 02/02/2016 |
| Medicare PECOS PAC ID | 1759795370 |
|---|---|
| Medicare Enrollment ID | O20210122000041 |
News Archive
Patients with irritable bowel syndrome (IBS) have a significantly greater prevalence of early adverse life events , including general trauma as well as physical, emotional and sexual abuse, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.
Pooled analysis of three phase 1 and 2 clinical trials published online ahead of print in the journal Lancet Oncology show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small cell lung cancers (NSCLC).
The findings are based on a sample of over 1400 adults aged between 20 and 80, living in the centre of Sweden. All of them had been diagnosed with a malignant or benign brain tumour between January 1997 and June 2000.
Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiology's Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent reduction in LDL-cholesterol, compared with an increase of 5 percent for placebo (p<0.001). The trial also met all of its secondary and tertiary endpoints.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2018, the launches and uptake of reformulations of conventional analgesics will drive annual three percent growth in the acute pain drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154789352 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YA0400X | Counselor - Addiction (substance Use Disorder) | 37LC00165800 (New Jersey) | Secondary |
| 101YP2500X | Counselor - Professional | 37PC00391200 (New Jersey) | Primary |
| Provider Name | Sheri L Solinski |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1104011691 PECOS PAC ID: 9931400991 Enrollment ID: I20151216000516 |
News Archive
Patients with irritable bowel syndrome (IBS) have a significantly greater prevalence of early adverse life events , including general trauma as well as physical, emotional and sexual abuse, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.
Pooled analysis of three phase 1 and 2 clinical trials published online ahead of print in the journal Lancet Oncology show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small cell lung cancers (NSCLC).
The findings are based on a sample of over 1400 adults aged between 20 and 80, living in the centre of Sweden. All of them had been diagnosed with a malignant or benign brain tumour between January 1997 and June 2000.
Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiology's Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent reduction in LDL-cholesterol, compared with an increase of 5 percent for placebo (p<0.001). The trial also met all of its secondary and tertiary endpoints.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2018, the launches and uptake of reformulations of conventional analgesics will drive annual three percent growth in the acute pain drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
› Verified 7 days ago
News Archive
Patients with irritable bowel syndrome (IBS) have a significantly greater prevalence of early adverse life events , including general trauma as well as physical, emotional and sexual abuse, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.
Pooled analysis of three phase 1 and 2 clinical trials published online ahead of print in the journal Lancet Oncology show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small cell lung cancers (NSCLC).
The findings are based on a sample of over 1400 adults aged between 20 and 80, living in the centre of Sweden. All of them had been diagnosed with a malignant or benign brain tumour between January 1997 and June 2000.
Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiology's Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent reduction in LDL-cholesterol, compared with an increase of 5 percent for placebo (p<0.001). The trial also met all of its secondary and tertiary endpoints.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2018, the launches and uptake of reformulations of conventional analgesics will drive annual three percent growth in the acute pain drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
› Verified 7 days ago
I-u Behavioral Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 56 Brunswick Woods Dr, East Brunswick, NJ 08816 Phone: 732-685-3224 | |
Cathi Fischer Lcsw, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 573 Cranbury Rd, East Brunswick, NJ 08816 Phone: 732-651-8220 Fax: 732-651-8220 | |
J E Brown Network Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4 Cornwall Dr Ste 203, East Brunswick, NJ 08816 Phone: 908-669-9080 Fax: 908-669-9080 | |
Divine Recovery Therapy Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1 Auer Ct, East Brunswick, NJ 08816 Phone: 732-785-4323 | |
Markell Counseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 25 Kennedy Blvd, East Brunswick, NJ 08816 Phone: 732-257-6662 Fax: 732-257-5647 | |
Life Psychotherapy Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 6 Auer Ct, St D, East Brunswick, NJ 08816 Phone: 732-390-0007 Fax: 732-390-0017 | |
David M. Zeidwerg, D.o., Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 465 Cranbury Rd Ste 203, East Brunswick, NJ 08816 Phone: 732-254-6400 |